Blueprint Medicines Corporation
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (S…
Biotechnology
US, Cambridge [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | -0.06 | 3.76 | 3.76 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | 3.51 | -6.55 | -6.79 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 135.21 | 5.05 | 2.14 | |
| Cash | -9.85 | 10.52 | 11.67 | |
| Capex | 76.64 | -0.02 | -0.08 | |
| Free Cash Flow | -21.37 | -1.67 | -1.37 | |
| Revenue | 32.08 | 1.56 | 1.18 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | -5.98 | 0.92 | 0.98 | |
| Operating Margin | 43.86 | -0.82 | -1.46 | |
| ROA | -18.80 | 0.09 | -0.11 | |
| ROE | -66.22 | 0.29 | -0.85 | |
| ROIC | 25.85 | -0.09 | -0.13 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of BPMC is permitted for members.
5
Growth
The "Growth Entry" for the Focus of BPMC is permitted for members.
6
Leverage & Liquidity